Impact Biomedical (IBO) EBIT (2022 - 2026)

Impact Biomedical (IBO) has reported EBIT for 5 consecutive years, with -$702000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 39.12% year-over-year to -$702000.0; the trailing twelve-month figure through Jun 2026 stood at -$5.1 million (up 82.75% YoY), and the FY2024 full-year result was -$28.8 million, down 613.83% from the prior year.
• EBIT advanced to -$702000.0 in Q2 2026 per IBO's latest filing, from -$2.3 million in the prior quarter.
• Across five years, EBIT topped out at -$626000.0 in Q2 2024 and bottomed at -$26.2 million in Q4 2024.
• Historically, EBIT has averaged -$2.6 million across 5 years, with a median of -$1.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: EBIT plunged 2202.99% in 2024, then jumped 39.12% in 2026.
• Over 5 years, EBIT stood at -$1.0 million in 2022, then slipped by 10.37% to -$1.1 million in 2023, then slumped by 2202.99% to -$26.2 million in 2024, then surged by 96.39% to -$948000.0 in 2025, then climbed by 25.95% to -$702000.0 in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$702000.0, -$2.3 million, and -$948000.0 for Q2 2026, Q1 2026, and Q3 2025 respectively.